Modulation of constitutive and inducible hepatic cytochrome(s) P-450 by interferon beta in mice

被引:16
作者
Carelli, M [1 ]
Porras, MC [1 ]
Rizzardini, M [1 ]
Cantoni, L [1 ]
机构
[1] IST RIC FARMACOL MARIO NEGRI,I-20157 MILAN,ITALY
关键词
beta-naphthoflavone; cytochrome P-450 3A; cytochrome P-450 1Al; cytochrome P-450 2B1; drug metabolism; inflammation; interferons; phenobarbital;
D O I
10.1016/S0168-8278(96)80034-1
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Aims/Methods: Interferon beta is used as a therapeutic agent, but its effects on the hepatic cytochrome P-450-dependent drug metabolizing system have not yet been characterized. We investigated the effect of interferon beta on cytochrome P-450 in mice. Results: Interferon beta (2x10(5) units/mouse) significantly reduced total hepatic cytochrome P-450 (20%) and the activity of NADPH cytochrome C reductase (12%) 24 h after administration; lower doses had no such effect. Various monooxygenase activities were slightly reduced, the one most affected being 7-ethoxycoumarin O-deethylase (29%). In phenobarbital-treated mice, interferon beta reduced the induction of total cytochrome P-450 (22%), the activities of pentoxyresorufin O-deethylase (38%), benzyloxyresorufin O-dealkylase (30%), erythromycin N-demethylase (30%), 7-ethoxycoumarin O-deethylase (16%) and cytochrome P-450 2B1 (33%) and 3A (45%) proteins. In beta-naphthoflavone-treated mice, interferon beta lowered the induction of total cytochrome P-450 (18%), the activities of ethoxyresorufin O-deethylase (31%) and of 7-ethoxycoumarin O-deethylase (25%) and of cytochrome P-450 1A1 protein (31%). Conclusions: Thus it appears that induced cytochrome(s) P-450 were susceptible to interferon beta, this effect not being influenced by the type of inducer. Since various members of the same cytochrome P-450 subfamilies catalyze oxidation of drugs in humans, our findings have potential significance as regards the fate of drugs or exogenous compounds given to patients receiving interferon beta.
引用
收藏
页码:230 / 237
页数:8
相关论文
共 42 条
  • [1] INTERFERONS IN THE THERAPY OF SOLID TUMORS
    AGARWALA, SS
    KIRKWOOD, JM
    [J]. ONCOLOGY, 1994, 51 (02) : 129 - 136
  • [2] ARMSTRONG SG, 1993, MOL PHARMACOL, V43, P542
  • [3] Baron S, 1992, INTERFERON PRINCIPLE
  • [4] DEPRESSION OF LIVER DRUG-METABOLISM AND INCREASE IN PLASMA-FIBRINOGEN BY INTERLEUKIN-1 AND TUMOR NECROSIS FACTOR - A COMPARISON WITH LYMPHOTOXIN AND INTERFERON
    BERTINI, R
    BIANCHI, M
    VILLA, P
    GHEZZI, P
    [J]. INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, 1988, 10 (05): : 525 - 530
  • [5] BORNHEIM LM, 1990, MOL PHARMACOL, V38, P319
  • [6] BURKE MD, 1983, CHEM-BIOL INTERACT, V45, P243
  • [7] BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5
  • [8] CRAIG PI, 1990, MOL PHARMACOL, V38, P313
  • [9] CRIBB AE, 1994, J PHARMACOL EXP THER, V268, P487
  • [10] DELAPORTE E, 1993, DRUG METAB DISPOS, V21, P520